Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2006

01-04-2006 | Original Article

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

Authors: P. J. Hesketh, S. M. Grunberg, J. Herrstedt, R. de Wit, R. J. Gralla, A. D. Carides, A. Taylor, J. K. Evans, K. J. Horgan

Published in: Supportive Care in Cancer | Issue 4/2006

Login to get access

Abstract

Goals of work

Prevention of chemotherapy-induced nausea and vomiting (CINV) with standard antiemetics has been more difficult to achieve in female patients. Data from two phase III trials of the NK1 antagonist aprepitant were assessed for potential effect of gender on treatment response.

Patients and methods

1,044 patients receiving cisplatin (≥70 mg/m2) were randomly assigned to control regimen [ondansetron (O) 32 mg i.v. and dexamethasone (D) 20 mg p.o. on day 1; D 8 mg twice daily on days 2–4] or aprepitant (A) regimen (A 125 mg p.o. plus O 32 mg and D 12 mg on day 1; A 80 mg and D 8 mg once daily on days 2–3; and D 8 mg on day 4). The primary endpoint was overall complete response (no emesis and no rescue therapy over days 1–5). Data were analyzed by a modified intent-to-treat approach. Between-treatment comparisons for each gender were made using logistic regression.

Main results

Women comprised 42 and 43% of the aprepitant and control groups, respectively. In the control group, 41% of women had overall complete response compared with 53% of men. In the aprepitant group, 66% of women had overall complete response compared with 69% of men.

Conclusion

The addition of aprepitant may negate the adverse prognostic effect of female gender on the prevention of CINV in patients receiving highly emetogenic chemotherapy.
Literature
1.
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRef
2.
Binder W, Carmody J, Walker J (2000) Effect of gender on anti-inflammatory and analgesic actions of two kappa-opioids. J Pharmacol Exp Ther 292(1):303–309PubMed
3.
Bradesi S, Eutamene H, Theodorou V, Fioramonti L, Bueno L (2001) Effect of ovarian hormones on intestinal mast cell reactivity to substance P. Life Sci 68:1047–1056PubMedCrossRef
4.
Bradesi S, Eutamene H, Garcia-Villar R, Fioramonti J, Bueno L (2002) Stress-induced visceral hypersensitivity in female rats is estrogen-dependent and involves tachykinin NK1 receptors. Pain 102:227–234CrossRef
5.
Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL (2003) Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 74(2):102–112PubMedCrossRef
6.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M et al (2004) The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 40(3):403–410PubMed
7.
Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3(3):113–119PubMed
8.
9.
Flores CA, Shughrue P, Petersen SL, Mokha SS (2003) Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 118(3):769–778PubMedCrossRef
10.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17(9):2971–2994PubMed
11.
Hesketh PJ (1994) Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer 2(5):286–292PubMedCrossRef
12.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr D, Roila F, de Wit R et al (2003) The oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21(22):4112–4119PubMedCrossRef
13.
Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS (2003) Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol 26(1):12–15PubMedCrossRef
14.
Myles PS, Hunt JO, Moloney JT (1997) Postoperative ‘minor’ complications: comparison between men and women. Anaesthesia 52(4):300–306PubMedCrossRef
15.
Oh EJ, Thompson LP, Weinreich D (2000) Sexually dimorphic regulation of NK-1 receptor-mediated electrophysiological responses in vagal primary afferent neurons. J Neurophysiol 84(1):51–56PubMed
16.
Package Circular (2003) EMEND (aprepitant) Capsules. PDR Electronic Library. Ref Type: Electronic Citation
17.
Poli-Bigelli S, Rodriguez-Pereira J, Guoguang-Ma J, Carides AD, Eldridge K, Evans JK et al (2003) Addition of the NK1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer 97(12):3090–3098PubMedCrossRef
18.
Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64(5):1117–1122PubMedCrossRef
19.
Roila F, Donati D, Tamberi S, Margutti G (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10(2):88–95PubMedCrossRef
20.
Rugarn O, Hammar M, Theodorsson A, Theodorsson E, Stenfors C (1999) Sex differences in neuropeptide distribution in the rat brain. Peptides 20(1):81–86PubMedCrossRef
21.
Seynaeve C, De Mulder PH, Verweij J, Gralla RJ (1991) Controlling cancer chemotherapy-induced emesis. An update. Pharm Weekbl Sci 13(5):189–197PubMed
22.
Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 66(1):192–197PubMed
23.
Stadler M, Bardiau F, Seidel L, Albert A, Boogaerts JG (2003) Differences in risk factors for postoperative nausea and vomiting. Anesthesiology 98(1):46–52PubMedCrossRef
24.
Stieler JM (2003) Treatment options for chemotherapy-induced nausea and vomiting. Am J Cancer 2(1):15–26CrossRef
25.
Tavorath R, Hesketh PJ (1996) Drug treatment of chemotherapy-induced delayed emesis. Drugs 52(5):639–648PubMedCrossRef
26.
Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2(2):107–114PubMed
27.
Metadata
Title
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
Authors
P. J. Hesketh
S. M. Grunberg
J. Herrstedt
R. de Wit
R. J. Gralla
A. D. Carides
A. Taylor
J. K. Evans
K. J. Horgan
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0914-4

Other articles of this Issue 4/2006

Supportive Care in Cancer 4/2006 Go to the issue

Original Article

Is there a correlation between spirituality and anxiety and depression in patients with advanced cancer?

Forthcoming Meetings

Forthcoming Meetings

Original Article

An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer

Short Communication

Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients

Editorial

Communication and phase 1 clinical trial recruitment

Original Article

Dying with dignity according to Swedish medical students
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits